Please try another search
RUA Life Sciences plc, together with its subsidiaries, engages in the provision of polymers, services, and products to the medical device industry in Europe, the United States, and internationally. The company operates through Biomaterials, Contract Manufacture, Vascular, and Structural Heart segments. The Biomaterials segment operates as depository of the Intellectual Property and licensing rights to a range of biostable and implantable polymers, including Elast-Eon and ECSil. The Contract Manufacture segment provides sub-contract manufacturing, assembly, packing and services to the medical device. The Vascular segment develops bore polymer sealed grafts and soft tissue patches. The Structural Heart segment manufactures synthetic heart valves. The company was formerly known as AorTech International plc and changed its name to RUA Life Sciences plc in June 2020. RUA Life Sciences plc was incorporated in 1996 and is headquartered in Ayrshire, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
William Donald Brown | 59 | 2011 | Executive Chairman |
John McKenna | 70 | 2016 | Director of Clinical Marketing & Executive Director |
Lachlan Arthur Smith | 43 | 2022 | CFO & Director |
Geoffrey Alan Berg | 68 | 2018 | Independent Non-Executive Director |
John Louis Ely | 73 | 2018 | Independent Non-Executive Director |
Ian Leslie Ardill | 57 | 2021 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review